Here’s what you should know.
1. TheStreet joins several other analysts in downgrading the industry giant.
2. Yet, despite the recent downgrades, Boston Scientific still has 13 “buy” ratings, six “hold” ratings and a single “sell” rating.
3. Analysts attached an average price target of $31.06 per share to the stock.
More articles on supply chain:
Riverside Regional Surgery Center owner, 3 others charged in $8M healthcare fraud scheme: 5 things to know
ASC physician and equity ownership preferences — 14 statistics
What ASCs can do to reduce SSI
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
